Medicago Licenses China Rights for Flu Vaccine to Phillip Morris Co.
publication date: Sep 26, 2012
Medicago, a Canadian vaccines company, has out-licensed China rights to its pandemic and seasonal flu vaccines to Philip Morris Products, the cigarette maker, in a $12 million deal. PMP has owned a 40% stake in Medicago since 2008. In addition, Medicago signed an exclusive license for a portfolio of plant-based protein development technologies from PMP. The technology will allow Medicago to grow its vaccines on tobacco plants, a faster, less-expensive production method than the methods currently in use. More details...
Stock Symbol: (TSX: MDG)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.